These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 30266754)

  • 1. RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer.
    Zarei M; Lal S; Vaziri-Gohar A; O'Hayer K; Gunda V; Singh PK; Brody JR; Winter JM
    Mol Cancer Res; 2019 Feb; 17(2):508-520. PubMed ID: 30266754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells.
    Zarei M; Lal S; Parker SJ; Nevler A; Vaziri-Gohar A; Dukleska K; Mambelli-Lisboa NC; Moffat C; Blanco FF; Chand SN; Jimbo M; Cozzitorto JA; Jiang W; Yeo CJ; Londin ER; Seifert EL; Metallo CM; Brody JR; Winter JM
    Cancer Res; 2017 Aug; 77(16):4460-4471. PubMed ID: 28652247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant IDH1 is required for IDH1 mutated tumor cell growth.
    Jin G; Pirozzi CJ; Chen LH; Lopez GY; Duncan CG; Feng J; Spasojevic I; Bigner DD; He Y; Yan H
    Oncotarget; 2012 Aug; 3(8):774-82. PubMed ID: 22885298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors.
    Chitneni SK; Reitman ZJ; Spicehandler R; Gooden DM; Yan H; Zalutsky MR
    Bioorg Med Chem Lett; 2018 Feb; 28(4):694-699. PubMed ID: 29366652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.
    Molenaar RJ; Botman D; Smits MA; Hira VV; van Lith SA; Stap J; Henneman P; Khurshed M; Lenting K; Mul AN; Dimitrakopoulou D; van Drunen CM; Hoebe RA; Radivoyevitch T; Wilmink JW; Maciejewski JP; Vandertop WP; Leenders WP; Bleeker FE; van Noorden CJ
    Cancer Res; 2015 Nov; 75(22):4790-802. PubMed ID: 26363012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer.
    Burkhart RA; Pineda DM; Chand SN; Romeo C; Londin ER; Karoly ED; Cozzitorto JA; Rigoutsos I; Yeo CJ; Brody JR; Winter JM
    RNA Biol; 2013 Aug; 10(8):1312-23. PubMed ID: 23807417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants.
    Avellaneda Matteo D; Wells GA; Luna LA; Grunseth AJ; Zagnitko O; Scott DA; Hoang A; Luthra A; Swairjo MA; Schiffer JM; Sohl CD
    Biochem J; 2018 Oct; 475(20):3221-3238. PubMed ID: 30249606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
    Mohrenz IV; Antonietti P; Pusch S; Capper D; Balss J; Voigt S; Weissert S; Mukrowsky A; Frank J; Senft C; Seifert V; von Deimling A; Kögel D
    Apoptosis; 2013 Nov; 18(11):1416-1425. PubMed ID: 23801081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
    Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
    J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis.
    Tiburcio PDB; Xiao B; Berg S; Asper S; Lyne S; Zhang Y; Zhu X; Yan H; Huang LE
    Acta Neuropathol; 2018 Feb; 135(2):285-298. PubMed ID: 29288440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate.
    Sesanto R; Kuehn JF; Barber DL; White KA
    Biochemistry; 2021 Jun; 60(25):1983-1994. PubMed ID: 34143606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate.
    Dexter JP; Ward PS; Dasgupta T; Hosios AM; Gunawardena J; Vander Heiden MG
    J Biol Chem; 2018 Dec; 293(52):20051-20061. PubMed ID: 30381394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
    Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
    J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
    Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
    PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Insights for Inhibiting Mutant Heterodimer IDH1
    Juritz EI; Bascur JP; Almonacid DE; González-Nilo FD
    Mol Diagn Ther; 2018 Jun; 22(3):369-380. PubMed ID: 29651790
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Peeters TH; Lenting K; Breukels V; van Lith SAM; van den Heuvel CNAM; Molenaar R; van Rooij A; Wevers R; Span PN; Heerschap A; Leenders WPJ
    Cancer Metab; 2019; 7():4. PubMed ID: 31139406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TOF-SIMS analysis of an isocitrate dehydrogenase 1 mutation-associated oncometabolite in cancer cells.
    Park J; Na HK; Shon HK; Son HY; Huh YM; Lee SW; Lee TG
    Biointerphases; 2018 Jan; 13(3):03B404. PubMed ID: 29382206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells.
    Hujber Z; Petővári G; Szoboszlai N; Dankó T; Nagy N; Kriston C; Krencz I; Paku S; Ozohanics O; Drahos L; Jeney A; Sebestyén A
    J Exp Clin Cancer Res; 2017 Jun; 36(1):74. PubMed ID: 28578659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterozygous IDH1
    Wei S; Wang J; Oyinlade O; Ma D; Wang S; Kratz L; Lal B; Xu Q; Liu S; Shah SR; Zhang H; Li Y; Quiñones-Hinojosa A; Zhu H; Huang ZY; Cheng L; Qian J; Xia S
    Oncogene; 2018 Sep; 37(38):5160-5174. PubMed ID: 29849122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
    Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
    Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.